secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cartesian Therapeutics, Inc. (RNAC)
CIK:        0001453687
Form:       8-K
Filed at:   2025-08-07T23:59:59+00:00
Accession:  0001453687-25-000098
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cartesian Therapeutics reports Q2 net income $15.9M; initiates Phase 3 AURORA trial for Descartes-08 in MG
--------------------------------------------------------------------------------

- Cash, equivalents and restricted cash $162.1M as of June 30, 2025; expected to fund operations into mid-2027.
- Net income $15.9M ($0.51 basic EPS) vs $13.8M ($0.58 basic EPS) in Q2 2024.
- R&D expenses $14.9M, up from $12.7M, driven by Phase 3 AURORA trial costs.
- Preliminary Phase 2 data for Descartes-08 in SLE expected in 2H25; pediatric basket trial initiation also expected in 2H25.
- Phase 3 AURORA trial of Descartes-08 in myasthenia gravis dosed first participant in May 2025; primary endpoint at Month 4.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1453687/000145368725000098/0001453687-25-000098-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1453687/000145368725000098/rnac-20250807.htm
  HTML page:      https://secwatch.observer/filing/0001453687-25-000098

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer